AJANTPHARM2024-10-012024-12-31 AJANTPHARM2024-10-012024-12-31 AJANTPHARM2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member AJANTPHARM2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member AJANTPHARM2024-12-31 AJANTPHARM2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member AJANTPHARM2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member AJANTPHARM2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member AJANTPHARM2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532331 AJANTPHARM NOTLISTED Ajanta Pharma Limited Equity 2024-04-01 2025-03-31 2025-01-30 2025-01-17 INR Crores Third quarter 13:30:00 15:20:00 2025-01-30 2025-01-30 Not applicable Single segment Pharmaceutical 2024-10-01 2024-12-31 Unaudited Consolidated 11461300000.00 304400000.00 11765700000.00 2101400000.00 785500000.00 -308800000.00 2651700000.00 79100000.00 359700000.00 3023200000.00 8691800000.00 3073900000.00 0.00 3073900000.00 948500000.00 -203400000.00 745100000.00 0.00 2328800000.00 0.00 0.00 0.00 0.00 2328800000.00 14400000.00 2343200000.00 2328800000.00 0.00 2343200000.00 0.00 250700000.00 2 18.60 18.59 0.00 0.00 18.60 18.59 1. The above consolidated unaudited financial results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 30 January 2025. The statutory auditors have expressed unmodified opinion on the results for the quarter and nine month period ended 31 December 2024. The review report has been filed with the stock exchange and is available on company website. 2. The consolidated unaudited financial results of the Company and its wholly owned subsidiaries (“the Group”) have been prepared as per Ind AS 110 on Consolidated Financial Statements. There is no minority interest. 3. Other income / Other expense includes : Rs. in Crore Quarter ended Nine months ended Year ended 31-Dec-24 30-Sep-24 31-Dec-23 31-Dec-24 31-Dec-23 31-Mar-24 Foreign exchange gain (in other income) 17.59 12.13 4.11 26.21 19.03 38.69 Foreign exchange loss (in other expense) - 25.65 7.58 13.88 - - 4. During nine month ended 31 December 2023, 25,325 (previous year 1,000) equity shares of Rs. 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Share Based Incentive Plan, 2019, resulting in an increase in the paid-up share capital by Rs. 50,650 (previous year Rs. 2,000) and securities premium by Rs. 3.84 crores (previous year Rs. 0.18 crores). 5. On 2 May 2024, Company has announced buy back of its 10,28,881 equity shares, being 0.82% of the total paid up equity share capital at Rs. 2,770 per equity share for an aggregate amount of Rs. 285.00 crores. The buy back opened on 05 June 2024, closed on 11 June 2024 and Company extinguished those shares on 27 June 2024. 6. The Group operates exclusively in one reportable business segment i.e., Pharmaceuticals . 7. The Financial Results are available for investors on the company's website www.ajantapharma.com and stock exchange websites www.nseindia.com and www.bseindia.com. Single segment 2024-04-01 2024-12-31 Unaudited Consolidated 34776900000.00 763900000.00 35540800000.00 6556400000.00 1696200000.00 -379200000.00 8099100000.00 146600000.00 1043300000.00 9180900000.00 26343300000.00 9197500000.00 0.00 9197500000.00 2503400000.00 -257200000.00 2246200000.00 0.00 6951300000.00 0.00 0.00 0.00 0.00 6951300000.00 -1900000.00 6949400000.00 6951300000.00 0.00 6949400000.00 0.00 250700000.00 2 55.52 55.49 0.00 0.00 55.52 55.49 Other Expenses 3023200000.00 Other Expenses 9180900000.00 Amount of items that will not be reclassified to profit and loss -6300000.00 Amount of items that will not be reclassified to profit and loss -67700000.00 -6300000.00 -67700000.00 -2200000.00 -23700000.00 Amount of items that will be reclassified to profit and loss 18500000.00 Amount of items that will be reclassified to profit and loss 42100000.00 18500000.00 42100000.00 0.00 0.00